Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    ep0042
Previous Study | Return to List | Next Study

Study to Evaluate the Safety and Tolerability of EP0042

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04581512
Recruitment Status : Recruiting
First Posted : October 9, 2020
Last Update Posted : February 8, 2023
Information provided by (Responsible Party):
Ellipses Pharma

Brief Summary:
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Myelodysplastic Syndromes Drug: EP0042 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Actual Study Start Date : November 2, 2020
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : December 2023

Arm Intervention/treatment
Experimental: EP0042 Drug: EP0042
EP0042 Oral 20 mg 50 mg capsules

Primary Outcome Measures :
  1. Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period. [ Time Frame: First cycle of treatment (28 Days) ]
    Incidence of dose-limiting toxicities (DLT)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  1. Male or female patients aged ≥ 18 years of age, at the time of informed consent, with histological or cytological confirmation of an advanced malignancy
  2. Ability to understand and provide written informed consent before any study-specific procedures, sampling, or analyses, including access to archival tumour tissue
  3. Ability to swallow and retain oral medication
  4. Sufficient life expectancy to allow the patient to complete at least 1 cycle (28 days) of the treatment period.
  5. ECOG Performance Status of 0, 1 or 2 at Screening
  6. In the opinion of the investigator, all other relevant medical conditions must be well-managed and stable for at least 28 days prior to first administration of study drug

    Part A (escalation phase) only:

  7. Patients with pathologically confirmed/documented AML or MDS, as defined by the 2017 European LeukaemiaNet (ELN) recommendations, or CMML, as defined by World Health Organization (WHO) criteria, who have relapsed from or are refractory to previous therapy

    Part B (Expansion cohort patients) only:

  8. Patients with pathologically confirmed/documented AML, as defined by the 2017 European LeukaemiaNet (ELN) recommendations, who either decline or are unsuitable for standard therapy, or who are refractory to, or have relapsed after, initial treatment, with no more than 3 prior lines of therapy. A prior line of therapy is defined as:

    • Treatment to induce remission with anthracycline/cytarabine (eg '3+7' daunorubicin 60 mg/m2 [3 days/cycle] plus cytarabine 100-200 mg/m2 [7 days/cycle], +/-midostaurin

      • mylotarg and including CPX-351, FLAG-ida or similar intensive regimens).
    • Low dose cytarabine or hypomethylating agents (azacitidine or decitabine)
    • Treatment with single agent FLT3 inhibitors (quizartinib, gilteritinib, crenolanib) for relapsed disease
    • Transplantation (allogeneic) in active disease.

    The following is not considered a prior line of therapy:

    • Consolidation cycles including those with midostaurin or mylotarg or quizartinib
    • Transplantation (allogeneic) given during remission. Other prior treatments may be discussed with the Medical Monitor for consideration.

    Approximately 20 evaluable patients will be included with FLT-3 ITD AML and approximately 10 evaluable patients with FLT-3 wild type AML, both confirmed by local laboratories within 28 days prior to dosing


  9. Female patients should either be of non-child-bearing potential or must agree to use highly effective methods of contraception from Screening until 6 months following administration of the last dose of study drug
  10. Male patients must use double barrier contraception from enrolment through treatment and for 6 months following administration of the last dose of study drug

Exclusion Criteria:

Patients with any of the following will not be included in the study:

Disease Under Study and Prior Anticancer Treatment:

  1. Suspected brain and/or leptomeningeal metastases that are symptomatic or untreated or that require current therapy
  2. Acute promyelocytic leukaemia (FAB:M3)
  3. Systemic anti-cancer therapy for the disease under study within 4 weeks of the first dose of study treatment. (Concomitant hydroxyurea is acceptable and will be permitted throughout the screening period and during first 2 cycles of study treatment)
  4. Ongoing toxic manifestations of previous treatments that have not reduced to at least CTCAE Grade 1. Exceptions to this are alopecia or certain Grade 2 treatment related toxicities, which in the opinion of the Investigator should not exclude the patient.
  5. Transplantation (allogeneic or autologous) within last 90 days, or on active immunosuppressive therapy for graft versus host disease in last 2 weeks Laboratory Parameters
  6. Patient with any out-of-range laboratory values defined as shown below. Haematology evaluations must be performed ≥7 days from any blood or blood product transfusion and ≥14 days from any dose of hematologic growth factor.

    • Serum creatinine > 1.5 x upper limit of normal (ULN) and/or creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 50 mL/min
  7. Inadequate liver function as demonstrated by

    • serum bilirubin ≥3 times the upper limits of normal range (ULN) or
    • alanine aminotransferase (ALT) ≥3 times the ULN or
    • aspartate aminotransferase (AST) ≥3 times the ULN or
    • AST or ALT ≥5 times the ULN in the presence of liver involvement by leukaemia

    Medical History and Concomitant Medications:

  8. Confirmed QTcF > 470 msec on screening ECG or congenital long QT syndrome
  9. Receiving an investigational anti-cancer treatment concurrently or within 14 days or five half-lives of either the parent drug or any active metabolite prior to the start of treatment with EP0042. Patients may receive hydroxyurea throughout the screening period and during the first 2 cycles of study treatment.
  10. Any evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize patient safety
  11. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, re-section of the stomach, extensive small bowel re-section that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery such as gastric bypass.
  12. Known history of human immunodeficiency virus infection (HIV) (testing is not required), active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection
  13. Hypersensitivity to EP0042 or D -α-Tocopherol polyethylene glycol succinate (TPGS)
  14. Malignant disease other than that being treated in this study, with the following exceptions:

    • Malignancies that were treated curatively and have not recurred within 2 years prior to study treatment
    • Completely resected basal cell and squamous cell skin cancers
    • Any malignancy considered to be indolent and that has never required therapy
    • Completely resected carcinoma in situ of any type
  15. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results
  16. Any major surgical procedure (in the investigator's judgement) within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumour biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary)
  17. Patients with a history of, or currently suffering from, severe psychiatric diseases such as mania, manic depression or psychoses
  18. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04581512

Layout table for location contacts
Contact: Katie Stoddart +44 (0) 2037430992
Contact: Tobi Arkenau +44 (0) 2037430992

Layout table for location information
Australia, Western Australia
Royal Perth Hospital Recruiting
Perth, Western Australia, Australia, 6000
Contact: Kanako Ohara   
Amsterdam UMC Recruiting
Amsterdam, Netherlands, 1081HV Amsterdam
Contact: Jeroen Janssen, Dr   
Erasmus MC Recruiting
Rotterdam, Netherlands, 3000 CA Rotterdam
Contact: Mojca Jongen-Lavrencic, Dr   
United Kingdom
The Royal Marsden Recruiting
London, UK, United Kingdom
Contact: David Taussig, Dr         
University College London Hospital Recruiting
London, United Kingdom, W1T 7HA
Contact: Jenny O'Nions, Dr   
Sponsors and Collaborators
Ellipses Pharma
Layout table for investigator information
Principal Investigator: David Taussig The Royal Marsden, UK
Layout table for additonal information
Responsible Party: Ellipses Pharma Identifier: NCT04581512    
Other Study ID Numbers: EP0042-101
First Posted: October 9, 2020    Key Record Dates
Last Update Posted: February 8, 2023
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Leukemia, Myeloid
Bone Marrow Diseases
Hematologic Diseases
Myelodysplastic-Myeloproliferative Diseases
Chronic Disease
Disease Attributes
Pathologic Processes